American Century Companies Inc. Acquires 18,625 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

American Century Companies Inc. boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 5.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 384,973 shares of the company’s stock after buying an additional 18,625 shares during the quarter. American Century Companies Inc. owned approximately 1.14% of Entrada Therapeutics worth $5,486,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. New York State Teachers Retirement System bought a new position in shares of Entrada Therapeutics during the 1st quarter valued at approximately $27,000. Acadian Asset Management LLC bought a new position in Entrada Therapeutics during the first quarter valued at $79,000. Allspring Global Investments Holdings LLC raised its stake in shares of Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after buying an additional 11,965 shares during the period. Rhumbline Advisers raised its stake in shares of Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after buying an additional 7,452 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Entrada Therapeutics by 13.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after buying an additional 14,838 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA opened at $15.40 on Wednesday. Entrada Therapeutics, Inc. has a fifty-two week low of $10.75 and a fifty-two week high of $18.17. The stock has a market cap of $519.89 million, a PE ratio of 24.44 and a beta of -0.24. The stock has a fifty day moving average of $15.79 and a 200-day moving average of $14.78.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. The business had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. On average, sell-side analysts predict that Entrada Therapeutics, Inc. will post 0.68 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 14th. Oppenheimer reissued an “outperform” rating and issued a $25.00 price target on shares of Entrada Therapeutics in a research report on Monday, August 26th.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, CEO Dipal Doshi sold 1,600 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.81, for a total value of $28,496.00. Following the completion of the transaction, the chief executive officer now directly owns 334,475 shares of the company’s stock, valued at approximately $5,956,999.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Entrada Therapeutics news, CFO Kory James Wentworth sold 1,758 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $14.95, for a total value of $26,282.10. Following the transaction, the chief financial officer now directly owns 81,412 shares in the company, valued at approximately $1,217,109.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dipal Doshi sold 1,600 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.81, for a total value of $28,496.00. Following the completion of the sale, the chief executive officer now directly owns 334,475 shares in the company, valued at approximately $5,956,999.75. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,636 shares of company stock valued at $214,057. Corporate insiders own 7.58% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.